New EULAR survey: Patients across Europe invited to share RMD experiences

FHS
June 14, 2024
2:26 pm

EULAR’s new survey seeks to gather valuable insights from patients across Europe on the impact of rheumatic and musculoskeletal diseases (RMDs).

FDA cracks down on off-label drug use messaging – Pharmaceutical Technology

The FDA acknowledged the usefulness of off-label uses for approved drugs for diseases with no approved therapies. Credit: klevo via Shutterstock The US Food and

October 24, 2023

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation

September 25, 2024

$187,000 pot leadership post opens up to nationwide search – The Cannabist

Related Articles The continued success of the Bay State’s legal weed business will need a “tough, strategic thinker” to oversee day-to-day administration of the agency

May 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.